EVENTS:   The Roaring 2020s or a Rerun of the 1970s? - Edward Yardeni/Yardeni Research - 24 Mar 26   Best Equity Short Ideas Conference Call 13 - Thomas Chanos/Badger Consultants & Dr. Aaron Fletcher/Bios Research & Jonathan Telgener/Channel Dynamics & Ed Steele/Iron Blue Financials & John Zolidis/Quo Vadis Capital & Mark Hiley/The Analyst - 26 Mar 26     ROADSHOWS: Chinese Equity Ideas & Channel Checks Across 50 sub-sectors - Don Ma /Horizon Insights   •   London   23 - 27 Mar 26       Long Short European Equity Research - Harry Grist /The Analyst   •   New York   26 Mar 26       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   27 - 27 Mar 26      
Filters

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Partners Group (PGHN SW) Switzerland

Financials

Forensic Alpha

The level of accrued revenue on the balance sheet stands at a massive CHF 739m - this might not seem like such a big increase from 2021 level of CHF 719m, but consider that performance fees in 2022 were only CHF 269m vs. CHF 1,197m in 2021. It therefore seems odd that the accrued revenue balance increased even while performance fees declined drastically. It is also odd that the "long-term" portion (not expected to convert to cash in the next 12 months) has hardly declined at all. Investors should seek clear explanations from management, especially given the risk around the recognition of performance fees has been picked up as a "Key Audit Matter" in the Auditor's report.

Edition: 157

- 31 March, 2023